reast cancer is the most common noncutaneous cancer and the second leading cause of cancer death among women in the United States. About 40 000 women die of breast cancer in the United States each year.
cal literature, is how to individualize mammography recommendations and foster informed decisions by patients. To accomplish this, clinicians must assess a patient's individual risk for breast cancer, effectively communicate the risks and benefits of screening, identify how a patient's characteristics might modify those risks and benefits, and elicit patients' personal preferences and values. This review will address the following key clinical questions: (1) What is the benefit of mammography screening, and how does that vary by age and patient risk? (2) What are the harms of mammography screening? (3) What is known about how to incorporate individual characteristics into breast cancer screening recommendations? (4) How can patients be supported in making informed decisions about mammography screening?
Methods
We searched MEDLINE for relevant randomized clinical trials (RCTs), meta-analyses, systematic reviews, and observational studies from 1960 to January 19, 2014 (search terms are reported in the eBox in Supplement). We also manually searched the references of key articles, reviews, meta-analyses, and practice recommendations. For describing the breast cancer mortality benefit of mammography we included meta-analyses of RCTs of mammography screening examining breast cancer mortality. From 525 articles identified, 20 metaanalyses met these criteria. We focused on the 5 meta-analyses published after 2006, when the most recent RCT, the Age Trial, 8 was published (eFigure 1 in Supplement).
To describe mammography's harms we focused on falsepositive results, unnecessary biopsies, and overdiagnosis, conducting 2 separate searches. The first included systematic reviews and meta-analyses through December 2008, the period for the review informing the 2009 USPSTF decision. 9 The second included primary studies and reviews published since December 2008. We identified 374 articles, including 14 systematic reviews or metaanalyses published before 2008 and 72 studies or reviews published after 2008 (eFigures 2 and 3 in Supplement). For studies on (1) individualizing information about risks and benefits and (2) communicating the benefits and risks to patients considering mammography screening, we searched for interventions (including decision aids) providing probabilistic information to women on the benefits and risks of screening, their own individual breast cancer risk, or both. We did not include interventions designed to increase screening rates without considering screening risks or a woman's baseline breast cancer risk. From 907 citations, we identified 23 studies (eFigure 4 in Supplement). From MEDLINE searches and reviews of citations, we additionally identified 25 articles on breast cancer risk models and using risk profiles to guide mammography decisions.
In Table 1 , we provide summary risk ratios and number needed to invite (NNI) to screening from Nelson et al's meta-analysis conducted for the USPSTF. 9 We also report absolute risk ratios calculated by inverting the NNI. 9 In Table 2 , we report estimated benefits and harms of breast cancer screening for 10 000 women undergoing annual mammography during a 10-year period. 
Results

Benefits of Screening Mammography
Between the 1960s and the 1990s, 8 large RCTs assessed breast cancer mortality associated with screening. Meta-analyses of these trials generally demonstrate a 15% to 20% decrease in the relative risk of breast cancer-specific mortality. The variation in estimates is largely attributable to differences in trial quality and inclusion criteria. The Edinburgh trial has been most consistently excluded because of concerns about its cluster randomization strategy. 24 However in other trials, concerns have been raised about randomization, contamination, and assignment of breast cancer mortality.
25
In addition, some argue that the RCTs are unlikely to be applicable to women undergoing screening today, because they preceded treatment advances that have powerfully influenced breast Table 1 shows estimates from the meta-analysis conducted for the USPSTF. 9 Despite similar relative benefits across age groups, because baseline breast cancer risk varies, the absolute benefit and NNI to screening to prevent 1 breast cancer death vary by age (Table 1) . Based on the meta-analysis by Nelson et al, 9 about 1904 women aged 39 to 49 would need to be invited to prevent 1 breast cancer death, vs 377 women aged 60 to 69. To address the "psychological magnification" of relative risks and most patients' limited numeracy, experts recommend using natural frequencies (eg, the number of cancers diagnosed among a certain number screened) to aid comprehension of such findings. 30,31 Table 2 provides published estimates from Welch and Passow of mammography's benefits using natural frequencies. Welch and Passow provide a range for number of breast cancer deaths in a screened population using results from RCTs with markedly contrasting results-the Canadian trials, which showed no significant breast cancer mortality benefit (Welch and Passow use a more conservative estimate of 5%) 10, 15 and the Swedish 2-County trial, which showed about a 36% risk reduction among those attending screening. 11 Welch and Passow calculated these numbers based on SEER 15-year breast cancer mortality rates 18 (assuming that the benefit of mammography would extend beyond the screening period) and adjusted for self-reported mammography rates in the United States, 19 providing a range to reflect the uncertainty about the benefit. Based on these estimates, among 10 000 women aged 50 years undergoing annual screening for 10 years, approximately 302 would be diagnosed with invasive breast cancer or DCIS, between 56 and 64 women would die of breast cancer despite screening, and between 3 and 32 breast cancer deaths would be averted through screening depending on the true effect of mammography. Some might argue that the ranges overemphasize extreme RCT results (concerns have been raised about suboptimal randomization in the Swedish trial 25 ) and may be difficult to communicate to patients, and that meta-analyses can at least provide a "best estimate." If Welch and Passow's methodology is used but Nelson et al's 9 meta-analysis results are applied to the adjusted SEER breast cancer death rates, among 10 000 women aged 40 years undergoing annual mammography for 10 years, 31 deaths would occur despite screening and 5 deaths would be averted; among 50-year-olds, 62 deaths would occur despite screening and 17 These numbers are from SEER incidence rates and reflect a combination of screened and unscreened women, so they would be higher in a completely screened population such as these 10 000 women by a number that depends on the magnitude of overdiagnosis. -approximately940(95%CI,740-1150) of the 10 000 women aged 50 years undergoing annual mammography reported in Table 2 .
Overdiagnosis
Overdiagnosis is the detection of a tumor through screening that would not have become clinically evident in the absence of screening. Overdiagnosis can occur either because of a tumor's indolent pathological features or because of competing mortality risks attributable to older age or comorbidities.
43 Previously overdiagnosis was considered primarily explained by DCIS, but it is now thought that some invasive cancer diagnoses also represent overdiagnosis; both types of cases are generally included in analyses, since both are treated. Treatment of an overdiagnosed cancer subjects a patient to the harms of treatment without benefits, since the tumor would not have caused problems if undetected.
43
There has been a sharp recent increase in studies examining overdiagnosis, and many authors now describe overdiagnosis as the most concerning potential harm of mammography screening. 44 However, substantial uncertainty exists around its magnitude. To measure overdiagnosis, ideally one would compare the number of cancers diagnosed in screened vs unscreened women with the same underlying risk factors and representing the same historical period and region, from the onset of screening until death.
43 Adequate follow-up time is needed to account for the lead time gained by screening and to avoid counting cancers detected early through screening as "excess," or overdiagnosed, cancers. 43 Long-term follow up of RCTs comparing screened with unscreened women minimizes these concerns, providing the best estimates of overdiagnosis.
45
Three RCTs, the Malmö trial and the 2 Canadian trials, never invited their control groups to screening, 10, 15, 20 allowing assessment of excess cancer incidence in the screened group 6 to 15 years after screening ended. A meta-analysis of overdiagnosis estimates from these 3 trials estimated that among women invited to screen, 19% of all cancers diagnosed during the screening period (and 11% during the entire observation period) were overdiagnosed. 44, 46 This proportion represents the excess incidence of cancers detected in the screened group over long-term follow-up, as a fraction of all cancers diagnosed in the screened group during the screening period (or the entire observation period). The RCT findings have limitations, including possible underestimation of overdiagnosis because some screening occurred in the control groups (in the Canadian National Breast Screening Study 1, 26.3% of the control group had at least 1 mammogram outside the study). 10, 47 Overestimation is also possible since women were not followed up until all had died, although in the recent update of the Canadian trials, excess cases still represented 22% of screeningdetected cancers. 27, 45 The applicability of the RCTs to women undergoing mammography screening today in the United States is also uncertain. 17 Because the Malmö trial screened women only every 18 to 24 months and used older, less sensitive mammography techniques, Welch and Passow used the Malmö estimate as a "lower bound" estimate of overdiagnosis risk.
17
Published estimates of overdiagnosis from observational studies vary from less than 5% to more than 50% 43,48-50 because of differing populations, assumptions, and measurement methods. 43 To identify incidence rates in the absence of screening, observational studies often use historical incidence rates or incidence in an unscreened geographical region. A recent study based on SEER incidence and survival trends using historical incidence rates as a comparison reported that 31% of all breast cancers diagnosed in the United States represented overdiagnosis. 21 Welch and Passow used these data as their "upper bound" estimate of overdiagnosis risk.
In Table 2 , we include Welch and Passow's lower and upper bound estimates to convey the uncertainty and methodological limitations around measuring overdiagnosis 17 ; the estimate from the metaanalysis of 3 RCTs (19%) 44 lies between these extremes. It is thus likely that among 10 000 women aged 50 years undergoing annual mammography for 10 years, of 302 cases of cancer or DCIS, between 30 and 137 would reflect overdiagnosis, with a best guess being 57 based on the meta-analysis estimate of 19%.
Individualizing Mammography Screening Decisions
For a woman in the United States, the average lifetime risk of breast cancer is about 12.3%; the 10-year risks of invasive breast cancer at ages 40, 50, and 60 years are 1.5%, 2.3%, and 3.5% respectively. 63 Similarly, a cost-utility model found that biennial screening among women aged 40 to 49 years with high breast density and either a first-degree relative with breast cancer or a history of a breast biopsy had similar ratios of benefits to harms as biennial screening of women in their 50s without those risk factors. 61 Of note, however, none of these models considered overdiagnosis in their main analysis.
61,63
If a healthy 40-year-old woman had twice the average risk of breast cancer because of dense breasts, she would be expected to have twice the absolute benefit of annual screening (eg, 10 lives saved per 10 000 instead of 5) ( Table 2 ). She would, however, also have a higher risk of false-positive findings.
22
Supporting Informed Decision-Making
Decisions about mammography should involve discussion of risks, benefits, uncertainties, alternatives, and patient preferences.
65,66
Although numerous interventions have aimed to increase mammography uptake, including interventions tailored to individuals' psychological readiness to adopt screening or to individuals' own risk profiles, [67] [68] [69] [70] [71] [72] [73] [74] [75] fewer studies examine measures of an informed decision as an outcome. A Cochrane review of RCTs examined the effects of personalized risk communication on informed decision making about screening for a range of diseases. 76 Eighteen studies focused on mammography screening; those assessing outcomes related to informed decisions generally showed an increase in knowledge, quality of life, and accuracy of risk perception with personalized risk communication. Notably, meta-analysis of 4 studies of interventions providing women with numerical information about their risk showed that among women 40 years or older, there was no association between provision of numerical information and uptake of mammography (odds ratio, 0.84 [95% CI, 0.68-1.03]). 76 Informed decisions require reconciling information about the risks and benefits of screening with a patient's values. Decision aids using pamphlets,videos,orInternettoolscanprovideinformation,elicitpreferences, and help patients make decisions. A Cochrane review 77 defineddecisionaidsas"interventionsdesignedtohelppeoplemakespecific and deliberative choices… by providing (at the minimum) information on the options and outcomes relevant to a person's health status,"andhelpingpatients"toclarify…thevaluetheyplaceontheben-efits, harms, and scientific uncertainties." Overall, decision aids increased knowledge, decreased decisional conflict and anxiety, and had variable effect on uptake of the test or treatment in question. The review's only mammography study recruited 70-year-old Australian women nearing the upper age cutoff for screening. 78 Exposure to the decision aid led to less indecision about continuing mammography, although there was no difference in screening participation the next month. A more recent study among US women 75 years or older administered a paper decision aid just before a primary care encounter. Women who received the decision aid reported knowing more about benefits and risks and screening, decreased intentions to be screened, and were less likely to undergo mammography in the following 2 years. 79 One RCT since the Cochrane review examined an online decision aid among women aged 38 to 45 years. 80 The decision aid summarized the risks and benefits of mammography and provided a val- However, a better understanding of overdiagnosis is needed to inform how individual characteristics influence the harms of mammography, and breast cancer risk models with better discriminatory accuracy are needed to more accurately individualize information about the benefits and harms of screening. In the meantime, the online Breast Cancer Risk Assessment Tool from the National Cancer Institute can assist physicians and patients in estimating risk.
The significance of the harms of mammography also depends on individuals' values and preferences, and eliciting these requires provision of accurate and balanced information and values clarification. In light of the harms and modest benefit of screening, as well as the substantial uncertainty surrounding their relative weight for individual patients, clinicians' efforts must focus on promoting informed screening decisions. The Box offers some suggestions for such discussions.
Given time constraints in primary care, decision aids may complement the points in the Box, laying the groundwork for discussions between clinicians and patients. Decision aids can facilitate informed decision-making and improve quality of care when there is no clear superior treatment or screening option. 82 Some cancers will be missed, and some women will die of breast cancer regardless of whether they are screened.
Many cancers will be found, but most women diagnosed with breast cancer will be cured regardless of whether the cancer was found by a mammogram.
Some cancers that are found would have never caused problems. This is called "overdiagnosis."
Often, women are called back for further testing because of an abnormality that is not cancer; this is called a "false-positive" result.
Studies of the benefits and harms of mammography have limitations and inconsistent results. The numbers reported below are estimates based on what most experts consider the best available evidence, but uncertainty about these estimates remains.
Benefits of Mammography
Mammography decreases the number of women who will die from breast cancer. This benefit is greater for women who are at higher risk for breast cancer based on older age or other risk factors such as family history.
The number of women whose lives are saved because of mammography varies by age. For every 10 000 women who get regular mammograms for the next 10 years, the number whose lives will be saved because of the mammogram by age group is approximately 5 of 10 000 women aged 40 to 49 years 10 of 10 000 women aged 50 to 59 years 42 of 10 000 women aged 60 to 69 years
If your breast cancer risk is higher than average, you may benefit more from a mammogram than someone with average risk.
Harms of Mammography
About half or more of women who have a mammogram yearly for 10 years will have a false-positive mammogram, and up to 20% of these women will need a biopsy. If you do decide to have a mammogram, you can anticipate that you will have at least 1 false-positive finding for which you are called back for additional images and perhaps a biopsy. Most of these findings are false alarms.
For some women undergoing regular screening, the mammogram may find an invasive cancer or noninvasive condition (ie, ductal carcinoma in situ) that would never have caused problems ("overdiagnosis"). We cannot tell which these are, so they will be treated just like all other cancers. Experts are uncertain of how frequently this happens, but estimates suggest that if a woman undergoing a screening mammogram is diagnosed with cancer or ductal carcinoma in situ, there is about a 19% chance that the cancer is being overdiagnosed, and she will receive unnecessary treatment.
Making a Decision About Mammography
Experts recommend that women aged 50 to 74 years undergo a screening mammogram every 2 years.
Whether you are likely to benefit from starting mammograms earlier or having them more frequently depends on your risks for breast cancer and your values and preferences.
Each woman may feel differently about the possibility of having a false-positive result or being diagnosed with and treated for cancer that might not have caused problems. It is important for you to consider what these experiences might mean for you. It is also important to consider how you might feel if you decide not to undergo screening mammography and you are later diagnosed with breast cancer, even if the likelihood that mammography would have made a difference is small. tion into practice. One challenge is how best to communicate the evidence. 30 Although natural frequencies are preferred, they are derived from absolute risks and require estimating individuals' baseline risk. 76 Research is needed on communicating scientific uncertainty, including regarding overdiagnosis. A recent qualitative study found that the influence of learning about overdiagnosis on screening intentions depended greatly on the magnitude of overdiagnosis presented. 83 Expert consensus on overdiagnosis, combined with improved understanding of how to describe this complex issue, may strengthen mammography decision aids.
Research will also be needed to explore the long-term effects of decision aids for screening decisions, especially since women with more information may actually be less likely to engage in screening. 76, 77 Provisions in the Affordable Care Act establishing shared medical decision making as a marker of quality of care could help speed development, dissemination, and evaluation of decision aids. 84 This review has provided a broad overview of key considerations in mammography screening decisions and the related areas of uncertainty. It has several limitations. We have relied on evidence of screening benefits from RCTs conducted decades ago in Europe and Canada, which may not generalize to US women today.
17, 85 Furthermore, reports about overdiagnosis are methodologically heterogeneous and controversial. The review does not address several other important facets of breast cancer screening, including the use of magnetic resonance imaging and newer mammography technologies. It also does not address the complex issue of DCIS.
Conclusions
Although some of the challenges of mammography can be resolved with further research to guide individualized decisions and thoughtful development and dissemination of decision aids, better breast cancer screening tests are needed. More sophisticated tools, for example, could distinguish aggressive vs indolent tumors, reducing the burden of overtreatment. 86 Mammography screening appears to be associated with reduced breast cancer mortality, but for some patients, the harms may outweigh the benefits. Until better screening methods are available, improved understanding of these harms, enhanced strategies to identify the highest-risk patients, and tools to help patients and clinicians incorporate these in their decisions should be research priorities.
